Rani Therapeutics Holdings Inc Cl A (RANI)

$0.94 +0.02 (2.56%)
Market Cap 113.24M
Revenue (ttm) 1.63M
Net Income (ttm) -29.67M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,820.25%
Debt to Equity Ratio 0.00
Volume 486,900
Avg Vol 1,092,434
Day's Range N/A - N/A
Shares Out 123.69M
Stochastic %K 59%
Beta 0.64
Analysts Strong Sell
Price Target $7.40

Company Profile

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company, focusing on technologies to enable the administration of biologics and drugs orally for patients, physicians, and healthcare systems with a alternative to painful injections in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes...

Industry: Biotechnology
Sector: Healthcare
Phone: 408 457 3700
Address:
2051 Ringwood Avenue, San Jose, United States
APRadek
APRadek Apr. 25 at 9:21 AM
$RANI Short selling is declining, and people are slowly realizing the potential.
0 · Reply
Fishbonee
Fishbonee Apr. 22 at 9:34 PM
$RANI -1.10 Before Weekend 📈
1 · Reply
Hi1254
Hi1254 Apr. 21 at 8:06 PM
$RANI $RR
0 · Reply
JaJadingdong1
JaJadingdong1 Apr. 21 at 2:18 PM
$RANI Looking good
0 · Reply
llchen1204
llchen1204 Apr. 21 at 12:58 PM
$RANI break $1
0 · Reply
wavw
wavw Apr. 20 at 7:49 PM
$RANI need a break…some good news will double here..
0 · Reply
wavw
wavw Apr. 20 at 6:19 PM
$RANI any number above $2 is fine.
0 · Reply
lordBrian
lordBrian Apr. 20 at 5:16 PM
$RANI I want 120
0 · Reply
wavw
wavw Apr. 20 at 2:18 PM
$RANI 49% held by institutions. Up from 27% in 3-4 months.
0 · Reply
BinaryLogic
BinaryLogic Apr. 20 at 6:35 AM
$RANI [Again]
0 · Reply
Latest News on RANI
Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Apr 9, 2026, 7:00 AM EDT - 16 days ago

Rani Therapeutics Appoints Dr. Sara Kenkare-Mitra as Strategic Advisor to Advance Platform and Clinical Strategy

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Mar 26, 2026, 4:05 PM EDT - 4 weeks ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Mar 25, 2026, 4:53 PM EDT - 4 weeks ago

Rani Therapeutics Appoints Jesper Høiland as Head of Strategy to Advance Corporate and Pipeline Prioritization

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Mar 19, 2026, 4:05 PM EDT - 5 weeks ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Jan 28, 2026, 7:00 AM EST - 3 months ago

Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Jan 8, 2026, 7:00 AM EST - 3 months ago

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Nov 24, 2025, 4:05 PM EST - 5 months ago

Rani Therapeutics to Participate in the Evercore Healthcare Conference

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Nov 6, 2025, 4:30 PM EST - 6 months ago

Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Oct 30, 2025, 8:00 AM EDT - 6 months ago

Rani Therapeutics to Present Preclinical Data on Oral Delivery of Semaglutide via the RaniPill® Capsule at ObesityWeek® 2025

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Oct 23, 2025, 4:05 PM EDT - 6 months ago

Rani Therapeutics Announces the Appointments of Abe Bassan and Vasudev Bailey, Ph.D. to Board of Directors

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 23, 2025, 4:01 PM EDT - 6 months ago

Rani Therapeutics Announces Closing of Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

Oct 20, 2025, 9:42 AM EDT - 6 months ago

CRMD, RANI, CELC, RAPT: four biotech stocks flying high today and why

CELC CRMD RAPT

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Oct 17, 2025, 7:48 AM EDT - 6 months ago

Rani Therapeutics signs up to $1.09 billion licensing deal with Japan's Chugai Pharma

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Oct 17, 2025, 7:31 AM EDT - 6 months ago

Rani Therapeutics Announces Oversubscribed $60.3 Million Private Placement Priced At-the-Market under Nasdaq Rules

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Oct 17, 2025, 7:30 AM EDT - 6 months ago

Rani Therapeutics Announces up to $1.085 Billion Collaboration with Chugai Pharmaceutical Co. for Multiple High-Value Therapeutics Including Rare Disease and Immunology Programs and Announces Concurrent Oversubscribed $60.3 Million Financing

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Aug 7, 2025, 4:05 PM EDT - 9 months ago

Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Jul 15, 2025, 9:00 AM EDT - 10 months ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $3.0 Million Registered Direct Offering

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Jul 14, 2025, 5:00 AM EDT - 10 months ago

Rani Therapeutics and ProGen Announce Late Breaking Presentation at ENDO 2025 Demonstrating Bioequivalence of Novel, Bispecific GLP-1/GLP-2 Receptor Agonist Delivered Orally via RaniPill Compared to Subcutaneous Delivery

Rani Therapeutics Announces Research Agreement with Chugai

May 19, 2025, 8:00 AM EDT - 1 year ago

Rani Therapeutics Announces Research Agreement with Chugai

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

May 13, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Mar 31, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Rani Therapeutics Announces Preclinical Data Demonstrating Bioequivalence of RT-114, a GLP-1/GLP-2 Dual Agonist (PG-102) Delivered Orally via the RaniPill® Capsule, to Subcutaneously Administered PG-102

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Mar 25, 2025, 6:00 PM EDT - 1 year ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Oct 15, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering and Cancellation of Certain Existing Warrants

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Oct 8, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit

Rani Therapeutics to Participate in September Investor Conferences

Sep 3, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in September Investor Conferences

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Aug 6, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics Reports Second Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics to Participate in August Investor Conferences

Jul 29, 2024, 4:05 PM EDT - 1 year ago

Rani Therapeutics to Participate in August Investor Conferences

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Jul 22, 2024, 8:30 AM EDT - 1 year ago

Rani Therapeutics Holdings, Inc. Announces Pricing of $10.0 Million Registered Direct Offering

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

Jun 24, 2024, 7:00 AM EDT - 1 year ago

Rani Therapeutics Announces Partnership with ProGen on Development of Oral Obesity Treatment

Rani Therapeutics to Participate in May Investor Conferences

May 14, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Participate in May Investor Conferences

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

May 9, 2024, 8:00 AM EDT - 2 years ago

Rani Therapeutics to Present Clinical and Preclinical Data on Oral Delivery of an Ustekinumab Biosimilar via the RaniPill® Capsule at Digestive Disease Week 2024

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

May 6, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Mar 20, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Mar 15, 2024, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Dec 14, 2023, 8:00 AM EST - 2 years ago

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Nov 8, 2023, 4:05 PM EST - 2 years ago

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Oct 19, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Oct 12, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Sep 18, 2023, 8:00 AM EDT - 2 years ago

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Sep 7, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Aug 11, 2023, 4:05 PM EDT - 2 years ago

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Jun 21, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Jun 8, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Jun 5, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

Rani Therapeutics to Present at the Jefferies Healthcare Conference

Jun 1, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics to Present at the Jefferies Healthcare Conference

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

May 31, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

May 24, 2023, 8:00 AM EDT - 3 years ago

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

May 10, 2023, 4:05 PM EDT - 3 years ago

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

APRadek
APRadek Apr. 25 at 9:21 AM
$RANI Short selling is declining, and people are slowly realizing the potential.
0 · Reply
Fishbonee
Fishbonee Apr. 22 at 9:34 PM
$RANI -1.10 Before Weekend 📈
1 · Reply
Hi1254
Hi1254 Apr. 21 at 8:06 PM
$RANI $RR
0 · Reply
JaJadingdong1
JaJadingdong1 Apr. 21 at 2:18 PM
$RANI Looking good
0 · Reply
llchen1204
llchen1204 Apr. 21 at 12:58 PM
$RANI break $1
0 · Reply
wavw
wavw Apr. 20 at 7:49 PM
$RANI need a break…some good news will double here..
0 · Reply
wavw
wavw Apr. 20 at 6:19 PM
$RANI any number above $2 is fine.
0 · Reply
lordBrian
lordBrian Apr. 20 at 5:16 PM
$RANI I want 120
0 · Reply
wavw
wavw Apr. 20 at 2:18 PM
$RANI 49% held by institutions. Up from 27% in 3-4 months.
0 · Reply
BinaryLogic
BinaryLogic Apr. 20 at 6:35 AM
$RANI [Again]
0 · Reply
wavw
wavw Apr. 17 at 9:34 PM
$RANI the volume is higher every day. Seems shorts covering…
0 · Reply
Fishbonee
Fishbonee Apr. 17 at 4:29 PM
$RANI 📈
0 · Reply
lisaparsons
lisaparsons Apr. 17 at 2:30 AM
$RANI well the ARS, we are done my friends.
4 · Reply
wavw
wavw Apr. 15 at 8:05 PM
$RANI everyone got trapped
0 · Reply
Jack696
Jack696 Apr. 15 at 8:04 PM
$RANI Great day today. soooo close to 1+. Hopefully the MMs won't dump over night and allow this thing to grow
0 · Reply
TheePharoah
TheePharoah Apr. 15 at 7:26 PM
$RANI In the words of WWE Superstar " The Rock "....... " Can you smell what the Rani is cooking ?" 😁
0 · Reply
Fishbonee
Fishbonee Apr. 15 at 7:09 PM
$RANI 📈
0 · Reply
GWaldorf5040
GWaldorf5040 Apr. 15 at 6:11 PM
$RANI taking off
0 · Reply
BBTAAPL
BBTAAPL Apr. 15 at 5:43 PM
$RANI what’s going on?
1 · Reply
Oleks14
Oleks14 Apr. 15 at 5:42 PM
$RANI Why is it so quiet?😄
0 · Reply
Fishbonee
Fishbonee Apr. 15 at 1:40 PM
$RANI
0 · Reply
llchen1204
llchen1204 Apr. 15 at 1:36 PM
$RANI curling back up
0 · Reply